Key result
Transcatheter aortic valve implantation has rapidly expanded its target population from inoperable patients to individuals with intermediate risk scores due to refined technology and experience.
Key points are not available for this paper at this time.
Broadens TAVI eligibility to intermediate-risk patients; leaves open long-term durability versus surgery.
Transcatheter aortic valve implantation (TAVI) is a minimally invasive and life-saving treatment in patients with aortic valve stenosis. As a consequence of increased operator experience and the refinement of valve technology, the target population of TAVI has rapidly expanded from inoperable patients to individuals with an intermediate risk score (1-3).
No takes yet. Share an insight, caveat, or question.
Vlastra et al. (2017) studied this question. Transcatheter aortic valve implantation has rapidly expanded its target population from inoperable patients to individuals with intermediate risk scores due to refined technology and experience.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: